Open-Label Extension and Safety Study of Talazoparib

Official Title

A Single-arm, Open-label, Multicentre, Extended Treatment, Safety Study In Patients Treated With Talazoparib


This is a single-arm, open-label, extended treatment, safety study in patients treated with talazoparib in qualifying studies.

Trial Description

Primary Outcome:

  • Safety as assessed by percentage of patients with any Adverse Event (AE), AE leading to Study Drug Discontinuation, AE leading to death, Serious Adverse Event (SAE), AE related to study drug, SAE related to study drug

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society